Concord Biotech Limited
NSE: CONCORDBIO · Pharmaceuticals · sector
₹1,311.20NSE close 2026-10-26
Key numbers
Market cap₹13,717 cr
Price₹1,311.20
52w high / low₹1,615 / ₹987
P/E50.2xSector median 27.9x
P/B6.8xSector median 2.9x
Book value₹192.8
Dividend yield0.81%Sector median 0.48%
ROE14.4%Sector median 11.7%
ROCE17.9%Sector median 12.3%
OPM34.7%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA34.5xSector median 18.6x
Interest cover1,386.3x
Current ratio7.39x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹416 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 1,386.3x in the last 12 months.
- Operating cash flow was below net profit in 2 of the last 3 years (FY25, FY24).
- Revenue was higher than a year earlier in 2 of the last 4 quarters.
- Other income was 19% of net profit in the last 12 months.
- Debtor days went from 125 (FY24) to 159 (FY26).
- Dividend paid in 2 of the last 3 financial years.
- Price ₹1,311.20 on 2026-10-26: -18.8% from the 52-week high, +32.8% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹2,382.35 · low ₹1,016.20
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 257 |
| EBITDA | 137 | 98 | 190 | 61 | 88 | 96 | 119 | 82 |
| OPM % | 44.1% | 40.1% | 44.3% | 30.1% | 35.8% | 34.5% | 36.3% | 32.0% |
| Other income | 10 | 15 | 9 | 14 | 13 | 10 | 15 | 13 |
| Net profit | 96 | 76 | 140 | 44 | 64 | 64 | 89 | 59 |
| EPS (₹) | 9.15 | 7.26 | 13.42 | 4.21 | 6.03 | 6.08 | 8.46 | 5.52 |
| Revenue YoY | -20.3% | +13.7% | -24.1% | +26.2% | ||||
| Profit YoY | -33.6% | -15.1% | -36.8% | +32.8% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|
| Revenue | 1,017 | 1,200 | 1,055 | 1,108 |
| EBITDA | 432 | 506 | 364 | 385 |
| Net profit | 308 | 372 | 261 | 275 |
| EPS (₹) | 29.45 | 35.52 | 24.78 | 26.09 |
| Revenue growth | +18.0% | -12.1% | -6.7% | |
| Profit growth | +20.6% | -29.8% | -22.7% | |
| Dividend / share (₹) | – | 8.75 | 10.70 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | -6.7% |
| Net profit | – | – | -22.7% |
| EPS | – | – | – |
| Share price | – | -19.4% (2y) | -16.6% |
Balance sheet
| ₹ cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Shareholders' equity | 1,527 | 1,813 | 2,017 |
| Borrowings | 6 | 0 | 0 |
| Cash & equivalents | 291 | 318 | 416 |
| Total assets | 1,701 | 2,034 | 2,235 |
| Fixed assets | 572 | 792 | 786 |
| Capital work in progress | 211 | 50 | 78 |
| Investments | 0 | 18 | 85 |
| Receivables | 350 | 522 | 460 |
| Inventory | 208 | 240 | 326 |
| Payables | 94 | 113 | 102 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Cash from operations | 265 | 245 | 267 |
| Cash from investing | -155 | -160 | -143 |
| Cash from financing | -99 | -99 | -113 |
| Capex | 86 | 111 | 95 |
| Free cash flow | 180 | 133 | 172 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| ROE % | 20.2% | 20.5% | 12.9% |
| ROCE % | 26.9% | 27.4% | 17.0% |
| Debtor days | 125 | 159 | 159 |
| Inventory days | 331 | 286 | 485 |
| Payable days | 150 | 135 | 151 |
| Cash conversion cycle (days) | 306 | 310 | 493 |
| Working capital days | 271 | 289 | 374 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 44.09% |
| FIIs | 7.28% |
| DIIs | 10.95% |
| of which Mutual funds | 5.84% |
| of which Insurance | 4.26% |
| Public (non-institutions) | 37.68% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.09% |
| Promoter group | % |
|---|---|
| Sudhir Kumar Vaid | 28.84% |
| Manju Vaid | 9.55% |
| Sudman Consultants Llp | 4.54% |
| Ankur Sudhir Vaid | 0.56% |
| Vaid Megha Ankur | 0.52% |
| Sonal Kumra | 0.07% |
| Gaurav Kumra | 0.01% |
| Aarav Vaid | 0.00% |
| Myra vaid | 0.00% |
| Concord Lifegen Limited | 0.00% |
| Clean Max Everglades Private Limited | 0.00% |
| Concord Biotech Japan KK | 0.00% |
| Celliimune Biotech Private Limited | 0.00% |
| Stellon Biotech Inc. | 0.00% |
| Public holders above 1% | % |
|---|---|
| Aryavir Jhunjhunwala Discretionary Trust | 8.03% |
| Aryaman Jhunjhunwala Discretionary Trust | 8.03% |
| Nishtha Jhunjhunwala Discretionary Trust | 8.03% |
| Dsp Small Cap Fund | 3.21% |
| Government Pension Fund Global | 2.95% |
| Tata Aia Life Insurance Co Ltd Unit Linked Multi Cap Fund | 2.68% |
| Axis Max Life Insurance Limited Ac Reversionary Bonus Participating Equity | 1.33% |
| Ravindra Raichand Dharamshi | 1.20% |
| Chanakya Corporate Services Pvt Ltd | 1.11% |
| Sbi Healthcare Opportunities Fund | 1.06% |
88,365 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| CONCORDBIO | ₹13,717 cr | 50.2x | 6.8x | 14.4% | 17.9% | 34.7% | – | 0.81% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-07-24 | Dividend | Dividend - Rs 7.55 Per Share |
| 2025-09-03 | Dividend | Dividend - Rs 10.70 Per Share |
| 2024-06-21 | Other | Annual General Meeting |
| 2024-06-21 | Dividend | Dividend - Rs 8.75 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacturing of pharmaceuticals: Research, development, manufacturing and sale of active pharmaceutical ingredients
- Manufacturing of pharmaceuticals: Research, development, manufacturing and sale of finished formulations
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | CONCORDBIO |
| BSE code | 543960 |
| ISIN | INE338H01029 |
| Face value | ₹1.0 |
| Incorporated | 1984-11-23 |
| Website | www.concordbiotech.com |
| Plants (India / abroad) | 4 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.